#Eccogene

2 stories

Clinical Trials June 7, 2026 · View digest

AstraZeneca Elecoglipron Adds China Phase 1b Detail at ADA 2026; VISTA and SOLSTICE Phase 2b Symposium Set for Monday

Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.

Clinical Trials June 4, 2026 · View digest

AstraZeneca and Eccogene's Oral GLP-1 Elecoglipron Adds a China Phase 1b Late-Breaker to Its ADA 2026 Slate Alongside VISTA and SOLSTICE

Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.